Service is in preparation Official β release coming soon. Some features are still being adjusted.

Investical Earnings & investing calendar Earnings & investing calendar
/
GENBNASDAQ

Generate Biomedicines, Inc.

Generate Biomedicines, Inc.
Loading price data…
Loading price data…
Chart type
Interval
Moving averages
Up/down colors

Share screenshot

Recent & upcoming events

Aug 6
Earnings 16:00
Q2 earnings
Add to Google Calendar
May 7
Earnings Time TBD
Q1 earnings
Add to Google Calendar
Dec 31
Est.
IPO 7:00
New listing (scheduled)
Add to Google Calendar

KPI highlights

FY25
Revenue $32M YoY +55.9%
Operating income $-235M margin -737.0%
Net income $-223M YoY —
EPS $-2.18 YoY —
P/E —
ROE 35.8% Sign disagrees with net income (may reflect a one-time accounting item)

Quarterly fundamentals

Income & cash flow Unit: $1M
Quarter FY25 Q1FY26 Q1
Revenue 8.827.22
Operating income -48.2-64.1
Net income -44.3-61.7
Operating CF -43.1-53.3

Company news

F-Score (Piotroski)

2/7 3 of 7 items lack data

Checks financial health against 9 criteria and shows how many are met as a fraction (more ✓ marks is healthier). Items with no data are shown as “—” — they're simply excluded from judgment, not counted against the score.

ROE and related signals above include a period where the sign disagrees with net income due to a one-time accounting item (see the ROE note in the KPI highlights above).

— Positive ROAExcluded from this period due to the net income/ROE sign mismatch N/A
✗ Positive operating cash flow $-215M
— ROA improved YoYExcluded from this period due to the net income/ROE sign mismatch N/A
✓ Operating CF exceeds net income (accrual quality) OCF $-215M / net income $-223M
✗ Equity ratio improved* Substitute for the original “decrease in long-term debt” -84.0% → -188.7%
— Current ratio improved No data
— No dilution (shares outstanding did not increase) No data
— Gross margin improved No data
✓ Asset turnover improved 0.04× → 0.10×

This score is reference information based on our own financial metrics. It is NOT a credit rating issued by a credit rating agency under Article 66-27 of the Financial Instruments and Exchange Act, and is NOT investment advice or a recommendation. Make investment decisions at your own responsibility.

Fact checklist

FY25
Equity ratio -188.7%
Current ratio —
Years of positive operating CF 0 of last 2 yrs
Payout ratio 0%
Latest fiscal year result Loss (net loss $223M)

Performance history

Last 10 years
$0M$8M$16M$24M$32M FY24FY25

Income & assets

Unit: $1M
Item FY24FY25
Revenue 20.531.9
Operating income -197-235
Ordinary income ——
Net income -181-223
Total assets 518330
Equity -435-623

A “—” means data wasn't available for that period — it's not a display error or an unusual value.

Indicators & cash flow

Unit: $1M
Item FY24FY25
EPS $-2.09$-2.18
ROE 41.7%35.8%
Operating CF -111-215
Investing CF -57.7117
Financing CF 90.227.0
FCF -121-204

Source: Twelve Data (fetched 2026-06-16) *Some metrics supplemented from additional sources

Key financial metrics

High ROE ✓

Sector positioning

Relative standing within the sector
Is this information incorrect?

Data provided by Twelve Data